Aligos Therapeutics (NASDAQ:ALGS) Stock Price Up 4.2% – Here’s What Happened

Aligos Therapeutics, Inc. (NASDAQ:ALGS) shares traded up 4.2% during mid-day trading on Tuesday . The company traded as high as $4.37 and last traded at $4.25. Approximately 87,495 shares changed hands during trading, a decline of 72% from the average session volume of 308,959 shares. The stock had previously closed at $4.08.

Analysts Set New Price Targets

A number of analysts recently weighed in on ALGS shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Aligos Therapeutics in a research note on Friday, May 29th. Lake Street Capital assumed coverage on shares of Aligos Therapeutics in a research note on Thursday, May 28th. They issued a “buy” rating and a $45.00 price objective on the stock. Wall Street Zen upgraded shares of Aligos Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Sunday, May 17th. Finally, Weiss Ratings lowered Aligos Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, Aligos Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.50.

Aligos Therapeutics Trading Up 2.5%

The company has a market cap of $26.96 million, a PE ratio of -0.50 and a beta of 2.26. The stock has a fifty day simple moving average of $5.45 and a two-hundred day simple moving average of $6.60.

Aligos Therapeutics (NASDAQ:ALGS) last posted its quarterly earnings results on Thursday, May 7th. The company reported ($2.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.29) by $0.08. Aligos Therapeutics had a negative return on equity of 139.47% and a negative net margin of 1,919.68%.The firm had revenue of $2.83 million for the quarter, compared to the consensus estimate of $0.25 million. As a group, equities research analysts anticipate that Aligos Therapeutics, Inc. will post -7.47 EPS for the current fiscal year.

Institutional Trading of Aligos Therapeutics

A number of institutional investors have recently added to or reduced their stakes in ALGS. Woodline Partners LP acquired a new position in Aligos Therapeutics during the first quarter worth about $2,602,000. Marshall Wace LLP acquired a new stake in shares of Aligos Therapeutics during the 4th quarter valued at approximately $2,504,000. Bank of America Corp DE boosted its stake in shares of Aligos Therapeutics by 1,652.8% during the 1st quarter. Bank of America Corp DE now owns 229,754 shares of the company’s stock worth $1,707,000 after acquiring an additional 216,646 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Aligos Therapeutics by 22.8% during the 3rd quarter. Vanguard Group Inc. now owns 171,689 shares of the company’s stock worth $1,683,000 after acquiring an additional 31,913 shares in the last quarter. Finally, SummitTX Capital L.P. grew its holdings in shares of Aligos Therapeutics by 6.7% in the 1st quarter. SummitTX Capital L.P. now owns 148,799 shares of the company’s stock worth $1,106,000 after acquiring an additional 9,375 shares during the period. Hedge funds and other institutional investors own 60.43% of the company’s stock.

Aligos Therapeutics Company Profile

Aligos Therapeutics, Inc is a clinical‐stage biopharmaceutical company dedicated to the discovery and development of novel therapeutics for chronic viral infections. The company leverages proprietary nucleic acid chemistry and small‐molecule discovery platforms to create therapies aimed at reducing viral replication, lowering antigen levels and restoring host immune function. Its pipeline includes both oligonucleotide conjugates and orally administered small molecules designed to address the root causes of persistent infections.

Founded in 2014 and headquartered in South San Francisco, California, Aligos advances its programs through strategic collaborations with academic institutions, research hospitals and industry partners.